338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Peter Schmid; Yeon Hee Park; Eva Muñoz-Couselo; Sung-Bae Kim; Joohyuk Sohn; Seock-Ah Im; Esther Holgado; Theodoros Foukakis; Sherko Kümmel; Rebecca Dent; Yuan Sun; Lingkang Huang; Jennifer Yearley; Petar Jelinic; Vassiliki Karantza; Javier Cortés

doi:10.1136/jitc-2021-SITC2021.338

Article info

Regular and Young Investigator Award Abstracts

Clinical Trials Completed

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Free

Authors

Peter Schmid Centre for Experimental Cancer Medicine, London, UK PubMed articles Google scholar articles
Yeon Hee Park Samsung Medical Center, Seoul, Korea, Republic of PubMed articles Google scholar articles
Eva Muñoz-Couselo Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain PubMed articles Google scholar articles
Sung-Bae Kim Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of PubMed articles Google scholar articles
Joohyuk Sohn Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of PubMed articles Google scholar articles
Seock-Ah Im Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of PubMed articles Google scholar articles
Esther Holgado Ramón y Cajal University, Madrid, Spain PubMed articles Google scholar articles
Theodoros Foukakis Karolinska Institutet and Breast Cancer Center, Theme Cancer, Karolinska University Hospital, Solna, Sweden PubMed articles Google scholar articles
Sherko Kümmel Kliniken Essen-Mitte, Essen, Germany PubMed articles Google scholar articles
Rebecca Dent International Breast Cancer Center Quironsalud Group, Singapore, Singapore PubMed articles Google scholar articles
Yuan Sun Merck and Co., Inc., Kenilworth, NJ, USA PubMed articles Google scholar articles
Lingkang Huang Merck and Co., Inc., Kenilworth, NJ, USA PubMed articles Google scholar articles
Jennifer Yearley Merck and Co., Inc., Kenilworth, NJ, USA PubMed articles Google scholar articles
Petar Jelinic Merck and Co., Inc., Kenilworth, NJ, USA PubMed articles Google scholar articles
Vassiliki Karantza Merck and Co., Inc., Kenilworth, NJ, USA PubMed articles Google scholar articles
Javier Cortés Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain PubMed articles Google scholar articles

Citation

Schmid P, Park YH, Muñoz-Couselo E, et al

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.338

Publication history

First published November 10, 2021.

Online issue publication

March 30, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password